Director at Structure Therapeutics (NASDAQ: GPCR) gets 39,453 options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Structure Therapeutics Inc. director Russell Angus C. received a grant of options covering 39,453 Ordinary Shares at an exercise price of $15.00 per share. The options vest in equal monthly installments over 12 months after June 17, 2026 and will be fully vested before the 2027 annual shareholder meeting. Following this award, he holds 39,453 derivative securities, which expire on June 16, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Russell Angus C.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	39,453	$0.00	--

Holdings After Transaction: Share Option (right to buy) — 39,453 shares (Direct, null)

Footnotes (1)

The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Key Figures

Option grant size: 39,453 options Exercise price: $15.00 per share Underlying shares: 39,453 Ordinary Shares +4 more

7 metrics

Option grant size 39,453 options Share Option (right to buy) granted to director

Exercise price $15.00 per share Option exercise price per Ordinary Share

Underlying shares 39,453 Ordinary Shares Underlying security linked to the option grant

Post-transaction derivative holdings 39,453 options Total options held following the grant

Option expiration date June 16, 2036 Expiration of granted options

Vesting period 12 months Equal monthly vesting after June 17, 2026

ADS to Ordinary Share ratio 1 ADS : 3 Ordinary Shares Representation of Ordinary Shares by ADSs

Key Terms

Share Option (right to buy), American Depositary Shares ("ADSs"), fair market value, vest in equal monthly installments, +1 more

5 terms

American Depositary Shares ("ADSs") financial

"based on the trading price of the Issuer's American Depositary Shares ("ADSs")."

American Depositary Shares (ADSs) are U.S.-listed certificates issued by a bank that represent ownership of a specified number of a foreign company’s ordinary shares, letting U.S. investors buy and sell those interests in U.S. dollars on American markets. They matter because they make investing in overseas companies as easy as buying a domestic stock—streamlining currency, settlement, and recordkeeping—while still exposing investors to foreign-market risks like exchange rates and local regulations.

fair market value financial

"exercise price per share is equal to the fair market value per Ordinary Share"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

vest in equal monthly installments financial

"The shares vest in equal monthly installments over the 12 months"

Ordinary Shares financial

"The Ordinary Shares of the Issuer may be represented by ADSs."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/18/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Angus C.

(Last)

(First)

(Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (right to buy)	$15⁽¹⁾	06/17/2026		A		39,453		⁽²⁾	06/16/2036	Ordinary Shares	39,453⁽³⁾	$0	39,453	D

Explanation of Responses:

1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,

3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

	/s/ Jun Yoon, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did the Form 4 filing report for Structure Therapeutics (GPCR)?

The filing reports a stock option grant to director Russell Angus C. for 39,453 Ordinary Shares at $15.00 per share. These options are compensation-related, not an open-market trade, and increase his derivative holdings to 39,453 options after the transaction.

How many options were granted to the Structure Therapeutics (GPCR) director?

The director received options over 39,453 Ordinary Shares. Each option has a $15.00 per share exercise price and represents the right to buy one Ordinary Share, which may be represented by American Depositary Shares, with three Ordinary Shares per ADS according to the disclosure.

What is the exercise price and expiry of the new GPCR options?

The options have an exercise price of $15.00 per Ordinary Share and expire on June 16, 2036. This long-dated expiration provides the director with a multi-year window to exercise the options once they have vested under the disclosed schedule.

How do the new Structure Therapeutics (GPCR) options vest?

The options vest in equal monthly installments over the 12 months following June 17, 2026. The disclosure states the grant will be fully vested immediately before the company’s 2027 annual shareholder meeting, subject to the applicable continued service conditions.

Are the Structure Therapeutics (GPCR) options linked to ADS trading prices?

Yes. The exercise price per Ordinary Share equals the fair market value on the grant date based on the trading price of the issuer’s American Depositary Shares. Each ADS represents three Ordinary Shares, as noted in the explanatory footnote to the transaction.

How many derivative securities does the GPCR director hold after this grant?

After the grant, the director holds 39,453 derivative securities, all from this option award. These options provide the right to acquire 39,453 Ordinary Shares, subject to the vesting schedule and the $15.00 per share exercise price disclosed in the filing.